Skip to content
‹ Back to IndustriesHealthcare

Revolutionizing Pharmaceutical Ethics: UK’s ABPI Code of Practice Ushers in a New Era of Self-Regulation

The UK's ABPI Code of Practice is a pivotal self-regulatory framework guiding ethical conduct in the pharmaceutical industry. With upcoming updates in 2024, stakeholders are preparing for significant changes in operational and ethical standards. Key topics include the role of QR codes and enhancements to the signatory process.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Healthcare · · Code ClarityDr. Joe DicapiteRina NewtonUk Abpi Code of Practice
Share
Revolutionizing Pharmaceutical Ethics: UK’s ABPI Code of Practice Ushers in a New Era of Self-Regulation

Key takeaways

01

The ABPI Code of Practice is crucial for ethical self-regulation in the UK pharmaceutical industry.

02

Anticipated 2024 updates will introduce validation requirements and streamline processes.

03

Innovative uses of QR codes in promotional materials will enhance accessibility.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In a dynamic era where the intersection of healthcare, regulation, and technology demands constant vigilance, the UK's ABPI Code of Practice stands as a testament to the pharmaceutical industry's commitment to self-regulation. Amidst a backdrop of historical challenges and technological advancements, this code serves as the rulebook guiding the ethical conduct of pharma companies within the UK. With the pharmaceutical landscape evolving at an unprecedented pace, the impending updates to the ABPI Code for 2024 have sparked a vital discussion on the balance between innovation, compliance, and patient safety.

The impending updates to the ABPI Code for 2024 have sparked a vital discussion on the balance between innovation, compliance, and patient safety.

What modifications can stakeholders expect in the 2024 iteration of the ABPI Code of Practice? How will these changes influence the operational and ethical frameworks of pharma companies in the UK?

Welcome to "Amend & Progress," a podcast brought to you by Vodori, dedicated to exploring the intricacies of promotional material review processes. Today, our host, Annalise Ludtke, delves into the anticipated updates to the UK's ABPI Code of Practice alongside two distinguished guests: Dr. Joe DiCapite, Director of Strategy for the UK and Europe at Vodori, and Rina Newton, co-founder of Code Clarity and a leading expert in code compliance.

In this enlightening conversation, they explore:

  • The essence and importance of the ABPI Code of Practice and its role in self-regulation.
  • The anticipated changes in the 2024 update, including the streamlining of the signatory process and the introduction of validation requirements for signatories.
  • The innovative use of QR codes in promotional materials to enhance access to prescribing information.

Dr. Joe DiCapite brings a wealth of experience in strategic planning and regulatory compliance, having extensively worked on navigating the complexities of the ABPI Code. Rina Newton, renowned for her expertise in code compliance, has played a pivotal role in shaping the dialogue around ethical practices within the pharmaceutical industry in the UK.

Vodori

Part of this channel

Vodori

Faster market access through compliant life science content review.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

Bon Secours Mercy Health affiliate HealthSpan Partners agreed to acquire Surgery Partners in a $5.7 billion deal. The chain reported $3.31 billion in revenue during 2025, according to Fierce Healthcare. Insurers in its 30 states may face a bigger negotiator.

  • 01Surgery Partners reported $3.31 billion in revenue for 2025, while Bon Secours Mercy Health reported just under $14 billion, according to Fierce Healthcare. That suggests outpatient surgery could become a major part of the system's business.
  • 02After the expected Q1 2027 close, watch insurer renewals covering both Bon Secours hospitals and Surgery Partners centers in its 30-state footprint.

Nov 2, 2026

Why CAHPS still swings Star Ratings at half its old weight

Why CAHPS still swings Star Ratings at half its old weight

mPulse’s Sam Oliver and Reva Sheehan said the CAHPS chapter moved with overall Medicare Advantage Star Ratings from 2026 to 2027 after CMS cut its weight from 4 to 2. With 11 administrative measures set to start leaving with the 2028 ratings and the equity reward cancelled, they outlined scenario planning around CAHPS, population mix and reweighting changes.

  • 01CMS cut CAHPS from a weight of 4 to 2 in the CY2025 final rule, effective with the 2026 Star Ratings, yet mPulse's chapter data shows CAHPS still moved in the same direction as overall stars for the 2027 cycle.
  • 02The April 2026 final rule removes 11 administrative measures, but none leave before the 2028 Star Ratings; the 2027 measure set is unchanged and the Health Equity Index reward is cancelled.
  • 03CAHPS stars are set by percentile cutoffs and reliability tests, and in the 2025 Star Ratings 13 percent of CAHPS results landed on a different star than the cutoff implied, 93 percent of them lower, according to RISE Health.

Nov 2, 2026

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Why ECG device makers may stop rebuilding arrhythmia analysis from scratch

Monebo's Kinetic Software Library provides ectopic beat detection, QRS feature extraction, and heart rate and rhythm analysis for ECG devices. For ECG device engineering and regulatory teams, rhythm analysis could become a choice between building it and licensing it.

  • 01Fifty-one later FDA clearances trace their predicate lineage to Monebo's earlier libraries, a track record anyone evaluating the new one can check.

Nov 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

H
Healthcare

Host, Amend & Progress

Annalise Ludtke hosts the 'Amend & Progress' podcast by Vodori, exploring updates and intricacies of pharmaceutical regulations. She facilitates discussions on material review processes and regulatory compliance alongside industry experts.

DJ
Dr. Joe DiCapite

Director of Strategy for the UK and Europe

Vidori

Dr. Joe DiCapite is a strategic planner and regulatory compliance expert with experience navigating the complexities of the ABPI Code. He plays a crucial role in adapting strategies for the UK and European markets.

RN
Rina Newton

Co-founder

Code Clarity

Rina Newton is a leading expert in code compliance, instrumental in shaping ethical dialogues in the UK pharmaceutical industry. She co-founded Code Clarity to enhance understanding of regulatory practices.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512